Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Tango Therapeutics (TNGX) EBITDA: 2020-2025

Historic EBITDA for Tango Therapeutics (TNGX) over the last 6 years, with Sep 2025 value amounting to $14.1 million.

  • Tango Therapeutics' EBITDA rose 142.80% to $14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$110.3 million, marking a year-over-year increase of 15.57%. This contributed to the annual value of -$130.2 million for FY2024, which is 33.01% down from last year.
  • Tango Therapeutics' EBITDA amounted to $14.1 million in Q3 2025, which was up 134.35% from -$41.0 million recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' EBITDA ranged from a high of $14.1 million in Q3 2025 and a low of -$42.5 million during Q1 2025.
  • Over the past 3 years, Tango Therapeutics' median EBITDA value was -$29.9 million (recorded in 2023), while the average stood at -$28.1 million.
  • As far as peak fluctuations go, Tango Therapeutics' EBITDA tumbled by 958,162.71% in 2021, and later surged by 142.80% in 2025.
  • Tango Therapeutics' EBITDA (Quarterly) stood at -$22.8 million in 2021, then decreased by 22.40% to -$27.9 million in 2022, then dropped by 7.12% to -$29.9 million in 2023, then plummeted by 36.84% to -$40.9 million in 2024, then skyrocketed by 142.80% to $14.1 million in 2025.
  • Its EBITDA was $14.1 million in Q3 2025, compared to -$41.0 million in Q2 2025 and -$42.5 million in Q1 2025.